ISOPTO ATROPINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ISOPTO ATROPINE (ISOPTO ATROPINE).
Antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, resulting in mydriasis and cycloplegia.
| Metabolism | Metabolized in the liver primarily via cytochrome P450 enzymes (CYP2D6) to tropic acid and tropine. |
| Excretion | Renal (70% as unchanged drug and metabolites within 24 hours); fecal (30%) |
| Half-life | 2.5-3.0 hours (terminal elimination half-life in adults); may be prolonged in elderly and children due to reduced metabolic clearance |
| Protein binding | 50% bound to plasma proteins (primarily albumin) |
| Volume of Distribution | 1.6 L/kg (large tissue distribution, including CNS and eye) |
| Bioavailability | Ophthalmic: systemic absorption via nasolacrimal duct and conjunctival vessels leads to measurable bioavailability; oral: 100% (not commercially available) |
| Onset of Action | Ophthalmic: 5-10 minutes (peak effect at 30-40 minutes) |
| Duration of Action | Ophthalmic: 7-14 days for mydriasis and cycloplegia; accommodative recovery may take up to 2 weeks |
1 to 2 drops of 1% solution in the affected eye(s) up to four times daily for cycloplegic refraction; for uveitis, 1 to 2 drops up to three times daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required; atropine is primarily metabolized in the liver and excreted in urine as inactive metabolites. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment due to potential decreased metabolism. |
| Pediatric use | Infants: 1 drop of 0.5% solution 30 minutes before procedure; Children: 1 drop of 1% solution 30 minutes before procedure. Maximum single dose: 0.5 mg (0.05 mL of 1% solution) to avoid systemic toxicity. |
| Geriatric use | Use lowest effective concentration (e.g., 0.5%) due to increased sensitivity and risk of systemic anticholinergic effects (e.g., confusion, urinary retention, increased intraocular pressure in narrow-angle glaucoma). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ISOPTO ATROPINE (ISOPTO ATROPINE).
| Breastfeeding | Atropine is excreted in human milk following systemic administration. M/P ratio not reported for ophthalmic use. However, after topical ocular administration, systemic absorption is low, but theoretical risk of infant anticholinergic effects (e.g., tachycardia, mydriasis, decreased feeding) exists. American Academy of Pediatrics considers systemic atropine compatible with breastfeeding, but topical use should be limited to the lowest effective dose. Monitor infant for signs of anticholinergic toxicity. |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, atropine sulfate administered subcutaneously to mice, rats, and rabbits at doses up to 10 mg/kg/day (approximately 600 times the maximum human ocular dose) produced no teratogenic effects. However, atropine crosses the placenta and may cause fetal tachycardia, mydriasis, and decreased amniotic fluid. First trimester: insufficient data to assess risk. Second and third trimesters: potential for fetal anticholinergic effects, including tachycardia and reduced amniotic fluid volume. Use only if potential benefit justifies potential risk. |
■ FDA Black Box Warning
No boxed warning.
| Serious Effects |
["Hypersensitivity to atropine or any component","Narrow-angle glaucoma or anatomically narrow angles","Uncontrolled acute-angle closure glaucoma","Adhesive iridocyclitis (risk of synechiae)"]
| Precautions | ["Elevated intraocular pressure in narrow-angle glaucoma","Systemic anticholinergic effects (tachycardia, hyperthermia, delirium) especially in children and elderly","Photophobia due to mydriasis","Risk of central nervous system disturbances in pediatrics","Use caution in patients with Down syndrome or brain damage (increased sensitivity)"] |
| Food/Dietary | No clinically relevant food interactions have been identified with ophthalmic atropine. Avoid taking by mouth. No restrictions on food or drink. |
Loading safety data…
| Fetal Monitoring | Monitor fetal heart rate for tachycardia if prolonged use or high doses. Maternal heart rate and blood pressure monitoring advised due to potential systemic absorption. Assess for maternal anticholinergic effects (dry mouth, blurred vision, urinary retention). In third trimester, monitor amniotic fluid volume if prolonged therapy. |
| Fertility Effects | No specific data on fertility effects in humans from ophthalmic atropine. Systemic anticholinergics may cause reversible sexual dysfunction (e.g., impotence, decreased libido) in males. In females, no known effect on ovulation or conception. Animal studies: atropine sulfate at doses up to 10 mg/kg/day (subcutaneous) had no effect on fertility in rats. |
| Clinical Pearls | Atropine ophthalmic solution is a potent antimuscarinic agent used for cycloplegic refraction and treatment of uveitis. Due to its long duration of action (up to 2 weeks), it is preferred for sustained mydriasis in inflammatory conditions. Nasolacrimal occlusion or gentle eyelid closure after instillation minimizes systemic absorption. Contraindicated in patients with narrow-angle glaucoma or predisposition to angle closure. In pediatric patients, use the lowest effective concentration (0.5%) to minimize systemic side effects such as flushing, tachycardia, and hyperthermia. |
| Patient Advice | Do not touch the dropper tip to any surface to prevent contamination. · Apply gentle pressure to the tear duct (inner corner of eye) for 1 minute after each drop to reduce absorption into the bloodstream. · Temporary blurred vision and light sensitivity are expected; avoid driving or operating machinery until vision clears. · Wear sunglasses outdoors to reduce photophobia. · Report eye pain, redness, or vision changes lasting beyond expected duration. · In infants and young children, watch for signs of systemic toxicity: flushed skin, rapid heartbeat, fever, or irritability. |